DALLAS - Instil Bio, Inc. (NASDAQ:TIL), a clinical-stage biopharmaceutical company, today disclosed that its Chinese partner, ImmuneOnco Biopharmaceuticals (HKEX:1541.HK), has commenced the phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) patients in China. ImmuneOnco, currently trading at $28.11, has seen a 12.9% price return over the past year according to InvestingPro data. The first patient has been dosed, marking a significant step in the investigation of this therapy.
The trial is designed to evaluate the safety and efficacy of IMM2510/SYN-2510, a PD-L1xVEGF bispecific antibody, as a treatment for NSCLC. ImmuneOnco plans to enroll first-line patients and expects to present initial clinical data as early as the second half of 2025. The company's stock is currently trading near its 52-week high of $31.98, showing strong market confidence in its clinical developments.
Instil also announced plans for a U.S. clinical trial targeting first-line NSCLC patients, with the initiation expected in the second half of 2025, pending regulatory approvals. "We anticipate that ImmuneOnco's initial clinical data of IMM2510/SYN-2510 in combination with chemotherapy in patients with front-line NSCLC could be extremely valuable in advancing our development of IMM2510/SYN-2510 in NSCLC," said Bronson Crouch, CEO of Instil.
IMM2510/SYN-2510 is distinguished from other bispecific antibodies in its class by its VEGF trap, which binds multiple VEGF receptor ligands, and enhanced antibody-dependent cellular cytotoxicity to target PD-L1-positive tumor cells.
Instil Bio focuses on developing novel therapies for solid tumor cancers, with SYN-2510 being their lead asset. InvestingPro analysis reveals that ImmuneOnco maintains a FAIR financial health score, though it faces challenges with weak gross profit margins. The company's progress and plans are subject to various risks and uncertainties, including those associated with clinical trial collaborations, the regulatory approval process, and competitive product candidates. For deeper insights into the company's financial health and additional ProTips, investors can access comprehensive analysis through InvestingPro.
This announcement is based on a press release statement and contains forward-looking statements. Actual results may differ materially from those projected due to various risks and uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.